MIGI Projected Dividend Yield
Mawson Infrastructure Group Inc ( NASDAQ : MIGI )Mawson Infrastructure Group a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, including dry eye syndrome (DES). Co. has in-licensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including Conjunctivochalasis (CCH) and Sjogren's syndrome (Sjogren's). LO2A is registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES, CCH and ophthalmological symptoms of Sjogren's and in the Netherlands for the treatment of DES and protection from dry eye as a result of Sjogren's. 20 YEAR PERFORMANCE RESULTS |
MIGI Dividend History Detail MIGI Dividend News MIGI Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |